Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Liver organoids: Current advances and future applications for hepatology

Yohan Kim, Minseok Kang, Michael Girma Mamo, Michael Adisasmita, Meritxell Huch, Dongho Choi

Clin Mol Hepatol. 2025;31(Suppl):S327-S348. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1040

View: 2346 Download: 286

Prediction and management of small-for-size syndrome in living donor liver transplantation

Jia-hao Law, Alfred Wei-Chieh Kow

Clin Mol Hepatol. 2025;31(Suppl):S301-S326. Published online December 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0870

View: 1163 Download: 100

Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation

Meng Sha, Jun Wang, Jie Cao, Zhi-Hui Zou, Xiao-ye Qu, Zhi-feng Xi, Chuan Shen, Ying Tong, Jian-jun Zhang, Seogsong Jeong, Qiang Xia

Clin Mol Hepatol. 2025;31(Suppl):S285-S300. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0323

View: 2119 Download: 178 Crossref: 2

Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications

Jaeho Park, Yi-Te Lee, Vatche G. Agopian, Jessica S Liu, Ekaterina K. Koltsova, Sungyong You, Yazhen Zhu, Hsian-Rong Tseng, Ju Dong Yang

Clin Mol Hepatol. 2025;31(Suppl):S255-S284. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0541

View: 2156 Download: 199 Web of Science: 1

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2025;31(Suppl):S228-S254. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0824

View: 5936 Download: 721 Web of Science: 7 Crossref: 10

Prediction and prevention of post-procedural bleedings in patients with cirrhosis

Alix Riescher-Tuczkiewicz, Pierre-Emmanuel Rautou

Clin Mol Hepatol. 2025;31(Suppl):S205-S227. Published online February 18, 2025

DOI: https://doi.org/10.3350/cmh.2024.0928

View: 1736 Download: 148

Hepatitis E as a trigger for acute-on-chronic liver failure

Maria Buti, Juan Carlos Ruiz-Cobo, Rafael Esteban, Mar Riveiro-Barciela

Clin Mol Hepatol. 2025;31(Suppl):S196-S204. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0758

View: 1778 Download: 142 Web of Science: 2 Crossref: 2

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 2090 Download: 168 Web of Science: 1 Crossref: 2

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 4411 Download: 337 Web of Science: 5 Crossref: 6

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(Suppl):S51-S75. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246

View: 6387 Download: 237 Web of Science: 3 Crossref: 3

Special Issue

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2025;31(Suppl):S1-S31. Published online February 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0045

View: 1408 Download: 171 Web of Science: 2 Crossref: 3

Reply to Correspondence

Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Jeayeon Park, Su Jong Yu

Clin Mol Hepatol. 2025;31(2):e221-e223. Published online March 4, 2025

DOI: https://doi.org/10.3350/cmh.2025.0226

View: 603 Download: 8

Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):e218-e220. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0070

View: 765 Download: 27

Correspondence

Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(2):e212-e214. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0100

View: 650 Download: 21

Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e210-e211. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1175

View: 1090 Download: 25

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e208-e209. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1171

View: 1103 Download: 23

Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0179

View: 597 Download: 19 Web of Science: 1 Crossref: 1

Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021”

Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):e200-e202. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0166

View: 972 Download: 31

TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Anja Tiede, Benjamin Maasoumy

Clin Mol Hepatol. 2025;31(2):e176-e179. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0135

View: 794 Download: 20 Crossref: 1

Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(2):e161-e162. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0121

View: 708 Download: 29

Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”

Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi

Clin Mol Hepatol. 2025;31(2):e155-e157. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0723

View: 1158 Download: 46

Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”

Ji Won Han, Dae Won Jun

Clin Mol Hepatol. 2025;31(2):e152-e154. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.1160

View: 1012 Download: 31

Letter to the Editor

Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”

Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li

Clin Mol Hepatol. 2025;31(2):e145-e148. Published online October 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0921

View: 1323 Download: 81

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Wei Wang, Yating Xie, Ailei Xu

Clin Mol Hepatol. 2025;31(2):e143-e144. Published online February 18, 2025

DOI: https://doi.org/10.3350/cmh.2025.0140

View: 757 Download: 35

Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Rui Shi, Minghua Wang

Clin Mol Hepatol. 2025;31(2):e137-e139. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.1159

View: 824 Download: 44 Web of Science: 1 Crossref: 1

MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song

Clin Mol Hepatol. 2025;31(2):e128-e133. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1008

View: 1352 Download: 76 Web of Science: 2 Crossref: 2

Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Hai Xu, Yong Zhou, Huikun Wu

Clin Mol Hepatol. 2025;31(2):e125-e127. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1087

View: 1016 Download: 33 Crossref: 1

Snapshot

Modulation of lymphatic vessels in management of liver disease and complications

Aarti Sharma, Pinky Juneja, Shiv K Sarin, Savneet Kaur

Clin Mol Hepatol. 2025;31(2):665-668. Published online October 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0793

View: 1121 Download: 65 Crossref: 1

Editorial

Metabolic dysfunction in patients following DAA-induced viral cure for HCV infection: A non-negligible risk to liver-related health: Editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Chen-Hua Liu, Yu-Ping Chang

Clin Mol Hepatol. 2025;31(2):658-661. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0155

View: 783 Download: 41 Web of Science: 2 Crossref: 2

Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Youxin Wang, Noriko Oza, Jazleen Leo, Ashok Choudhury, Daniel Q. Huang

Clin Mol Hepatol. 2025;31(2):654-657. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0133

View: 1317 Download: 71 Web of Science: 1 Crossref: 1

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Viewed By 11442	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7184	MAFLD: How is it different from NAFLD?
Viewed By 5478	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 5134	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4579	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 349	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 328	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 219	MAFLD: How is it different from NAFLD?
Cited By 113	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 110	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search